Rescheduling Medical Cannabis
A Turning Point for Oregon Healthcare and what Schedule III means for the Future of the OMMP
Salem Or. – For more than two decades, Oregon’s medical cannabis program has existed in a legal and regulatory gray area. Patients, healthcare providers, researchers, and policymakers have all been forced to navigate a system in which state law recognized cannabis as medicine while federal law continued to classify it as a Schedule I controlled substance
alongside heroin.
That landscape changed dramatically in 2026 when the federal government formally recognized medical cannabis as having accepted medical use and moved it to Schedule III of the Controlled Substances Act.
While the full implications of rescheduling will take years to unfold, one thing is already clear: the decision represents the most significant shift in cannabis policy since Oregon voters approved the Oregon Medical Marijuana Act in 1998.
For Oregon, the question is no longer whether cannabis has medical value. The question now is how the state integrates cannabis into healthcare while preserving the patient protections that have defined the Oregon Medical Marijuana Program (OMMP) for nearly 30 years.
What Rescheduling Means
The move to Schedule III places medical cannabis in the same federal classification as medications such as ketamine, testosterone, and certain codeine-containing products.
More importantly, it represents an acknowledgment by the federal government that cannabis has accepted medical use and may be prescribed or recommended for the treatment of medical conditions.
This shift removes one of the largest barriers to meaningful healthcare discussions about cannabis. For decades, many healthcare institutions, medical schools, insurers, and public health agencies have been reluctant to engage with cannabis because federal law maintained that it had no accepted medical use.
That argument is no longer available.
As a result, healthcare systems across the country will increasingly be forced to address cannabis not simply as a consumer product, but as a therapeutic tool with both benefits and risks.
Implications for Oregon Healthcare
The most immediate impact may be felt in healthcare education and patient care.
Many physicians, nurses, pharmacists, social workers, addiction specialists, and mental health providers receive little formal education regarding cannabis. Yet millions of Americans already use cannabis to manage pain, anxiety, sleep disorders, cancer symptoms, post-traumatic stress, and other conditions.
Rescheduling creates an opportunity for healthcare providers to receive evidence-based education regarding cannabis pharmacology, dosing, potential drug interactions, contraindications, and appropriate patient monitoring.
Oregon has already taken an important first step with the passage of House Bill 4142, which requires educational training for hospice, palliative care, and residential care facilities that permit medical cannabis use on their premises.
Many advocates view this as the beginning of a broader effort to integrate cannabis education throughout Oregon’s healthcare system.
Areas likely to see increased attention include chronic pain management, palliative and hospice care, cancer treatment support, mental and behavioral health services, substance use disorder treatment and recovery, veteran healthcare, long-term residential care
The goal is not to position cannabis as a cure-all or replacement for conventional medicine. Rather, it is to ensure that healthcare providers have the knowledge necessary to discuss cannabis honestly and effectively with patients who are already using it or considering it as part of their treatment plan.
A Critical Moment for the Oregon Medical Marijuana Program
While rescheduling creates opportunities, it also presents significant challenges for the OMMP.
The program has experienced a steady decline in enrollment since adult-use cannabis became available. Once serving nearly 80,000 patients, the program now serves approximately 12,000 registrants.
As enrollment has fallen, so has revenue generated through patient and grower fees. The result is an increasingly unsustainable funding model that threatens the long-term viability of the program.
Some policymakers may view rescheduling as a reason to fold medical cannabis entirely into Oregon’s adult-use marketplace.
However, doing so could eliminate many of the protections currently available to patients.
OMMP registrants continue to receive important benefits, including tax-exempt purchases, higher possession and cultivation limits, confidential patient registration, access to designated caregivers and growers, organizational caregiver designations for healthcare facilities, and legal protections specific to medical use
The challenge facing Oregon is determining how to modernize and sustain the OMMP without sacrificing these patient-centered protections.
Moving Beyond a Retail-Centered Model
Perhaps the most important consequence of rescheduling is that it changes the conversation.
For years, cannabis policy discussions have largely focused on retail sales, taxation, licensing, and regulation. While those issues remain important, medical cannabis now demands a healthcare framework as well.
That framework may include expanded research, healthcare provider education, patient protections, public health guidance, and eventually discussions about insurance reimbursement.
While Medicare and Medicaid reimbursement for cannabis remains uncertain, rescheduling removes one of the most significant barriers to those conversations. Future research demonstrating efficacy, safety, and cost savings could eventually support broader coverage discussions.
Public health agencies may also begin evaluating cannabis through the same lens used for other therapeutic substances—acknowledging both benefits and risks while focusing on evidence-based education rather than prohibition.
Looking Ahead
Rescheduling does not solve every challenge facing cannabis patients, nor does it answer every regulatory question. Significant uncertainty remains regarding federal oversight, insurance coverage, workplace protections, and the relationship between medical and adult-use markets.
What it does provide is an opportunity.
For Oregon, that opportunity is to build a modern medical cannabis framework that reflects both scientific evidence and patient experience.
The future of cannabis policy is no longer solely about access. It is increasingly about integration—integrating cannabis into healthcare, public health, research, education, and patient care in ways that are thoughtful, evidence-based, and centered on the needs of Oregonians.
The decisions made over the next several years may determine whether Oregon remains a national leader in medical cannabis policy or simply treats cannabis as another retail product. For patients, healthcare providers, and policymakers alike, the stakes have never been higher.